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Selective digestive decontamination (SDD) and
selective oropharyngeal decontamination (SOD)
have been associated with reduced mortality and
lower ICU-acquired bacteremia and ventilator-
associated pneumonia rates in areas with low
levels of antibiotic resistance. However, the effect
of selective decontamination (SDD/SOD) in areas
where multidrug-resistant Gram-negative bacteria
are endemic is less clear. It will be important to
determine whether SDD/SOD improves patient
outcome in such settings and how these measures
affect the epidemiology of multidrug-resistant
Gram-negative bacteria. Here we review the current
evidence on the effects of SDD/SOD on antibiotic
resistance development in individual ICU patients as
well as the effect on ICU ecology, the latter including
both ICU-level antibiotic resistance and antibiotic
resistance development during long-term use of
SDD/SOD.arguments concerning patient safety and ecological safetyIntroduction
Selective digestive decontamination (SDD) refers to
the prophylactic treatment of selected patients with
an oropharyngeal paste and enteral suspension con-
taining antimicrobials (usually tobramycin, colistin and
amphotericin B) as well as an intravenous antibiotic
during the first 4 days of ICU admission (usually a
second-generation cephalosporin). The purpose of the
treatment is to eradicate potential pathogenic micro-
organisms from the oropharynx and digestive tract of
patients at risk for nosocomial infections (ventilated
patients, neutropenic patients and neonates). The targeted
potential pathogenic microorganisms include aerobic
Gram-negative bacteria (GNB), methicillin-susceptible* Correspondence: N.L.Plantinga@umcutrecht.nl
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unless otherwise stated.Staphylococcus aureus and yeasts, and once a patient
has been successfully decolonized the unaffected anaer-
obic flora would offer prevention against new colonization
with potential pathogenic microorganisms, a principle
called colonization resistance [1]. Selective oropharyngeal
decontamination (SOD) consists of SDD without the
enteral suspension and without intravenous antibiotics.
Thirty years of selective decontamination (SDD/SOD)
studies include >50 randomized studies and >10
meta-analyses. In the most recent meta-analysis, pooled
analyses of the available evidence suggest that SDD and
SOD are associated with improved survival [2]. Yet the
amount of heterogeneity between studies owing to
differences in study designs, included patient populations,
interventions and diagnostic procedures justifies caution
in data interpretation. Moreover, beneficial effects
reported from more meta-analyses should not be
seen as cumulative evidence, because all analyses rely
on the same data. Notwithstanding these beneficial
effects, the risks associated with the prophylactic use
of antibiotics must also be considered. This debate is fed by
in an era of increasing antibiotic resistance. Arguments
against widespread use of SDD/SOD are supported by
reported outbreaks of antibiotic-resistant bacteria during
the use of SDD, development of secondary resistance
within patients exposed to SDD, and failing attempts to
control outbreaks by implementation of SDD. Arguments
pro SDD/SOD are supported by reports and a recent
meta-analysis about the absence of resistance develop-
ment during its use [3], and descriptions of outbreaks
that were actually constrained by SDD.
This nonsystematic review first aims to provide an
overview of the available data on the relationship between
use of SDD/SOD and antibiotic resistance in individual
patients admitted to ICUs with low levels of antibiotic
resistance. Although this will hamper extrapolation of
findings to other settings, the review does reflect a real-life
research setting in which an important reason for hetero-
geneity between units – that is, antibiotic resistanceAccess article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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settings can serve to design studies in settings with higher
levels of antibiotic resistance. Since a systemic review and
meta-analysis was performed in 2013 [3], this description
is limited to a selection of studies that – in our opinion –
best answer the question(s) addressed.
Secondly, we will review the effects of SDD/SOD on
the occurrence of ICU-level antibiotic resistance and on
antibiotic resistance development during long-term use.
These ecologic studies have mainly been performed in
ICUs with low levels of antibiotic resistance.
For completeness, findings of universal and targeted use
of SDD/SOD and antibiotic resistance in ICUs where
multidrug-resistant Gram-negative bacteria (MDR-GNB)
were endemic are summarized in table form. Finally, three
randomized controlled trials (RCTs) with SDD applied
specifically to patients colonized with MDR-GNB will be
discussed.
Selective decontamination and antibiotic
resistance in individual patients
In this nonsystematic review we describe the effects
of SDD/SOD on antibiotic resistance in individual patients
admitted to ICUs with low levels of antibiotic resistance,
as obtained from studies: that applied SDD/SOD in
all eligible patients (that is, not in specific subgroups
only); in ICUs with absence of endemicity with
methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant enterococci (VRE) or carbapenem-
resistant Enterobacteriaceae (CRE) and less than 10 % of
Gram-negative infections caused by extended-spectrum
beta-lactamases (ESBL); in which there was some form of
random treatment allocation, with reported data on the
occurrence of antibiotic-resistant GNB; and that were
published since 2000.
Most studies investigating selective decontamination used
individual patient randomization, creating a mixture of
patients receiving and not receiving SDD/SOD in the ICU.
In 2002 such an individual RCT randomizing SDD (topical
polymyxin and gentamicin, 4-day course of ciprofloxacin
intravenously) described no ‘remarkable differences
between the groups with respect to the isolation of
resistant bacteria’ from surveillance cultures [4]. When
comparing SDD with placebo, 5/265 versus 7/262 patients
developed infections with GNB resistant to ciprofloxacin,
4/265 versus 10/22 patients developed infections with GNB
resistant to gentamicin and 2/265 versus 18/262 patients
developed infections with GNB resistant to polymyxin.
de Jonge and colleagues were among the first to deter-
mine the effects of SDD when applied to all patients in
one unit, who were compared with patients treated in a
similar unit in which SDD was not used [5]. This clustered
approach is optimal to quantify the effects of interventions
in which patient dependency cannot be excluded, such asmeasures that prevent colonization and infection by
modulation of the unit-wide bacterial ecology, or
interventions that should reduce cross-transmission,
such as hand hygiene. During 24 months patients
were admitted to each unit based on the availability
of beds, and were randomized if beds were available
in both units. In this study, SDD was associated with
higher levels of antibiotic susceptibility of GNB to
ceftazidime, ciprofloxacin, imipenem and tobramycin.
VRE were isolated in four and five patients from the SDD
unit and the control unit, respectively, and MRSA was not
detected. Moreover, SDD was associated with a 35 %
reduction in ICU mortality.
In a French ICU, SDD was compared with chlorhexidine
body washing plus intranasal mupirocin and with placebo
in a 2 × 2 factorial design [6]. Proportions of patients
developing infections with colistin-resistant GNB ranged
from 11 % in patients receiving double placebo treat-
ments to 2 % among patients receiving both SDD and
chlorhexidine body washing/mupirocin (P = 0.005). A
similar (although nonsignificant) trend was observed
for tobramycin-resistant GNB infections, ranging from
17 % to 9 % in double placebo-treated patients and
SDD plus chlorhexidine/mupirocin-treated patients,
respectively.
Detailed information on antibiotic resistance is also
available from a multicenter cluster-randomized crossover
trial in 13 Dutch ICUs, in which (in random order) SDD,
SOD and standard care (that is, no SDD or SOD) were
compared during periods of 6 months per intervention
[7]. Almost 90 % of all patients that stayed in the ICU
for at least 48 hours were included. In this study,
ICU-acquired bacteremia with highly resistant microor-
ganisms (HRMO; mainly GNB) occurred less frequently
during SDD, as compared with SOD and standard care
(crude odds ratios (95 % confidence intervals): SDD vs.
SOD, 0.37 (0.16 to 0.85); SDD vs. standard care, 0.41 (0.18
to 0.94); SOD vs. standard care, 1.10 (0.59 to 2.07)) [8].
Furthermore, both SDD and SOD were associated with
less acquisition of respiratory tract colonization with most
relevant HRMO, with crude odds ratios (95 % confidence
intervals) of 0.58 (0.43 to 0.78) for SDD and 0.65
(0.49 to 0.87) for SOD as compared with standard
care [8]. Acquired respiratory tract colonization with
Enterobacteriaceae resistant to cefotaxime, to tobramycin
or intrinsically resistant to colistin – which are part of
SDD – occurred less frequently in patients receiving SDD,
as compared with those receiving standard care or SOD
[8]. Tobramycin resistance in glucose nonfermenting
GNB was highest during SDD [8].
Subsequent analyses on resistance development against
colistin revealed that acquisition rates of carriage with
colistin-resistant GNB were 0.8, 1.1 and 0.7 per 1,000
patient-days at risk during standard care, SOD and SDD,
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GNB to colistin-resistant strains were 0.5, 0.5 and 0.7 per
1,000 patient-days at risk. Yet these events occurred
(by definition) only in patients colonized with GNB,
and therefore conversion rates among colonized
patients were highest during SDD (1.1, 2.6 and 3.6
during standard care, SOD and SDD, respectively).
Moreover, conversion to colistin resistance occurred
preferentially in GNB already resistant to tobramycin.
It was concluded that, in Dutch ICUs, the prevalence of
colistin resistance was low and that resistance development
occurred infrequently and was not associated with
SDD/SOD, but that the presence of tobramycin resistance
increases the risk of secondary colistin resistance.
In another analysis, the effect of SDD on intestinal
decolonization was compared for patients with intestinal
colonization with Enterobacteriaceae that were either sus-
ceptible or resistant to cephalosporins or aminoglycosides
at the time of ICU admission [10]. Intestinal decolonization
rates were comparable for Enterobacteriaceae suscep-
tible to and resistant to cephalosporins (343/430 (80 %)
vs. 56/77 (73 %) respectively, P = 0.17). However, in
aminoglycoside-resistant Enterobacteriaceae, SDD was
less successful in eradication (368/457 (81 %) vs. 31/50
(62 %) for Enterobacteriaceae susceptible to versus re-
sistant to aminoglycosides, respectively; P < 0.01).
In the largest, and most recent, multicenter cluster-
randomized crossover study, SDD was compared with
SOD in 16 Dutch ICUs [11]. In this pragmatic study of
almost 12,000 patients, all patients with an ICU length
of stay >48 hours and all patients having received one
dose of SOD or SDD (that is, all patients with an expected
ICU length of stay >48 hours) were the eligible study
population (N = 11,997), thereby avoiding selection bias.
Cumulative incidences of ICU-acquired bacteremia
during SOD and SDD were 5.9 % and 4.6 %, respectively
(P = 0.002), and were 0.6 % and 0.4 % for episodes caused
by HRMO during SOD and SDD, respectively (P = 0.27).
In conclusion, the results from these large SDD/SOD
trials in settings with low levels of antibiotic resistance
strongly suggest that SDD and SOD can be safely used
in the treatment of ICU patients. Microbiological
surveillance, especially with regard to aminoglycoside
and colistin susceptibility, is recommended to monitor
development of antibiotic resistance.
Ecological effects of selective decontamination
The effect of SDD/SOD on antibiotic resistance is not only
relevant for patients treated with these antimicrobials, but
also for other and even future ICU patients. There are
two important questions to be answered concerning
the ecological effects of SDD/SOD.
First, what is the effect of SDD/SOD on ICU-level
bacterial ecology, more specifically on the prevalence ofantibiotic-resistant bacteria, in all patients? To answer
this question, we searched for studies that assessed
antibiotic resistance on an ICU level, either through
regular point-prevalence sampling of all patients present
in the ICU or by evaluation of routine cultures from all
admitted patients (rather than from those treated with
SDD/SOD only), and that had a control group, separated
from the intervention in time or location, for comparison.
Second, does the long-term use of SDD/SOD change
the prevalence of these bacteria? To answer this question
we searched for studies that had collected resistance data
during at least 3 years of SDD/SOD use, and in which
antibiotic resistance was assessed either by time-trend
analysis or by a comparison with an appropriate control
group.
Again, almost all studies addressing these questions have
been performed in settings with low levels of antibiotic
resistance.
ICU-level antibiotic resistance (short-term use of selective
decontamination)
In two Dutch cluster-randomized multicenter studies
with crossover, the ecological effects of SDD and SOD
on antibiotic resistance were monitored prospectively
with monthly point-prevalence surveys. These surveys
included all patients present in the ICU at a certain time
point, including those not receiving SDD or SOD. In the
first study – investigating standard care, SOD and
SDD in randomized order in 13 ICUs – completeness
of rectal and respiratory samples was 87 % and 82 %,
respectively [7]. Antibiotic resistance amongst Escherichia
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and
Enterobacter cloacae was lowest during SDD (as compared
with standard care and SOD) for all 16 pathogen–antibiotic
combinations as well as for multidrug resistance. In a post
hoc analysis of these data, the unit-wide prevalence of GNB
resistant to ceftazidime, tobramycin or ciprofloxacin in
rectal swabs was lowest during SDD, but the prevalence
was higher in the months thereafter, suggesting a rebound
effect [12]. In the second Dutch cluster-randomized study,
16 ICUs were randomized to 12 months of SDD and 12
months of SOD, in random order [11]. The unit-wide
prevalence of antibiotic-resistant microorganisms was again
measured with monthly point-prevalence surveys including
3,776 rectal specimens and 3,651 respiratory samples. The
prevalence of respiratory tract colonization with HRMO
was similar in both groups, but during SDD the prevalence
of rectal colonization with such bacteria was lower (7.3 %
during SDD vs. 12.7 % during SOD, P = 0.008). Yet the
prevalence of aminoglycoside-resistant GNB in rectal swabs
increased more pronouncedly during SDD (7 % per month
vs. 4 % during SOD, P <0.05). The previously observed re-
bound effect of ceftazidime resistance after discontinuation
of SDD was not confirmed in this study [12].
Plantinga and Bonten Critical Care  (2015) 19:259 Page 4 of 7ICU-level effects of SDD/SOD on the prevalence of
antibiotic-resistant GNB can also be measured through
analyzing microbiological samples from all ICU patients
(rather than from only patients receiving SDD/SOD or
through point-prevalence surveys – the latter method
precludes measurement of antibiotic resistance in all
SDD/SOD-treated patients). This method was used in a
single-center before–after study in France [13]. Here,
implementation of SDD (without systemic antibiotics)
was followed by a unit-wide reduction in the proportion
of patients with an ICU-acquired infection caused by
MDR-GNB; from 2.6 % 1 year before to 0.9 % during the
first year of SDD (P = 0.003).
Whether 6 to 12 months of SDD/SOD use exerts suffi-
cient antibiotic pressure to significantly increase antibiotic
resistance in settings where it is rare is uncertain. The
effects of long-term use of SDD/SOD will therefore be
described below.
Antibiotic resistance during long-term use of selective
decontamination
The effects of long-term use of SDD/SOD (at least 3
years) have been addressed in two multicenter studies
and two single-center studies. Two studies investigated
antibiotic resistance in specific isolates from all ICU
patients [14, 15], one study determined acquisition of
antibiotic-resistant GNB in SDD-treated patients using
surveillance and clinical microbiology results [16], and the
most recent study used point-prevalence samples [17].
In a German study, antibiotic resistance (MRSA, VRE,
tobramycin-resistant GNB) was evaluated during 5 years
of SDD in a single unit, and this was compared with
findings from 33 ICUs not using SDD [15]. Incidence
rates of MRSA and tobramycin-resistant P. aeruginosa
were lower in the ICU where SDD was used as compared
with the pooled data of the other ICUs, and the opposite
was observed for VRE, tobramycin-resistant E. coli and K.
pneumoniae. The increase in VRE was explained by a
hospital-wide outbreak and most episodes of carriage
with tobramycin-resistant Enterobacteriaceae were not
considered ICU acquired. The authors therefore concluded
that in their setting with low baseline resistance levels, with
a national surveillance program for resistance monitoring
and with an active screen-and-isolate protocol for MRSA,
SDD was safe during this period of time.
In a recent study, microbiological culture results from
respiratory samples from patients in 38 Dutch ICUs over
a period of 51 months were retrospectively analyzed
[14]. In 17 ICUs SDD or SOD had been used continuously,
in 13 ICUs SDD/SOD had not been used and in eight ICUs
SDD or SOD was introduced during the period of data
collection. Time-trend analyses did not reveal statisti-
cally significant increases in the occurrence of antibiotic-
resistant GNB in ICUs continuously using SDD or SOD,while resistance increased for some pathogen–antibiotic
combinations in ICUs not using SDD or SOD. In those
ICUs in which SDD or SOD was introduced, there was an
increase in colistin-resistant Enterobacteriaceae before
introduction, followed by a reduction in resistance after its
implementation.
In a Spanish ICU where SDD was the standard of care
(with addition of vancomycin for oxacillin-resistant S.
aureus carriers), both the prevalence of colonization
with antibiotic-resistant GNB and/or oxacillin-resistant
S. aureus on ICU admission as well as the incidence
density of acquisition (both colonization and infection)
with these bacteria during ICU admission were stable
during 5 years [16].
In a post hoc analysis from two Dutch multicenter
SDD/SOD studies [7,11], the unit-wide point prevalence
of colistin-resistant GNB and of tobramycin-resistant
GNB was compared during both study periods in five
hospitals that continued to use SDD between studies.
The average duration of uninterrupted SDD use between
studies was 3.8 years and the average duration of uninter-
rupted SDD/SOD use including the study periods was 6.4
years (range 5.6 to 7.4 years). For both SDD and SOD there
were nonsignificant reductions in resistance to both colistin
and tobramycin in both respiratory and rectal samples [17].
In summary, in these ecological studies SDD/SOD
appeared ecologically safe during longer periods of time
(3 to 6.4 years) in ICUs with relatively low levels of
antibiotic resistance. To the best of our knowledge
there are no studies, using similar methodology, with
different results. An international multicenter study
on the effects of SDD and SOD on ICU-level ecology
in countries with higher levels of antibiotic resistance is
currently ongoing (ClinicalTrials.gov: NCT02208154).
Nevertheless, even in countries with low levels of anti-
biotic resistance, such as the Netherlands, outbreaks with
resistant bacteria can occur while using SDD. In an attempt
to control an ongoing outbreak caused by ESBL-producing
and tobramycin-resistant K. pneumoniae, SDD was imple-
mented and the prevalence of colistin resistance in these
isolates increased from complete absence before introduc-
tion to 70 % (74 of 106 isolates) after introduction of SDD
[18]. Almost all isolates (71 of 74) belonged to one specific
clone. These findings illustrate that SDD should not be
used to control transmission of MDR-GNB if classical
control measures have failed.
Selective decontamination in ICUs with high
levels of antibiotic resistance
The effects of selective decontamination on antibiotic
resistance are less well studied in settings with high levels
of antibiotic resistance. We are aware of four observa-
tional studies and one small RCT (Table 1) that have been
performed in ICUs where MDR-GNB were endemic
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described by the authors), all using SDD, applied either as
universal treatment (n = 3) or as targeted treatment
for identified carriers (n = 3). Most of these studies
investigated the effects of SDD on elimination or per-
sistence of carriage with resistant strains, and ecologic
outcomes were not reported. Settings, study designs,
methods (random treatment allocation was performed in
one study only) and results differ extensively, precluding a
clear interpretation.
There are currently three RCTs evaluating the effects
of SDD to decolonize patients that are carriers of MDR-
GNB. However, these experimental studies, with 40 to
152 patients only, were all performed outside the ICU.
In a double-blind, placebo-controlled RCT in Switzerland,
58 hospitalized patients with intestinal carriage with
ESBL-producing Enterobacteriaceae (in absence of
infection) received either SDD (enteral colistin and
neomycin, oral nitrofurantoine for 5 days in case of
urinary tract carriage) or placebo [19]. Although SDD
yielded an immediate decline in intestinal ESBL-producing
Enterobacteriaceae carriage, treatment effects had disap-
peared 1 week after discontinuation of SDD.
In an Israeli hospital where CRE were endemic, the
effect of targeted SDD on intestinal carriage with
CRE was determined in a double-blind RCT [20].
Forty hospitalized patients with carbapenem-resistant
K. pneumonia colonization or infection were randomized
to 7 days of SDD (oropharyngeal and enteral gentamicin
and colistin) or placebo. Decolonization rates in the
intestinal tract after 1 week of SDD were 61.1 % with
SDD and 16.1 % with placebo, but this difference declined
at follow-up and was no longer significant after 5 weeks.
Secondary resistance to gentamicin or colistin was not
observed in any of the SDD-treated patients.
In an Israeli semi-RCT, patients with intestinal CRE
carriage – mainly Klebsiella species – were treated with any
of different SDD regimens (gentamicin for colistin-resistant
CRE, colistin for gentamicin-resistant CRE and randomized
allocation to colistin, gentamicin or both for CRE suscep-
tible to both antibiotics), and eradication rates were com-
pared with untreated patients (who did not consent to
intervention or had CRE resistant to both gentamicin and
colistin) [21]. Eradication of intestinal CRE carriage was
achieved in 22 of 50 patients (44 %) treated with any SDD
regimen and in seven of 102 untreated patients (7 %)
(P <0.001). Secondary resistance developed in seven
of the 50 SDD-treated patients (gentamicin resistance
in six of 26 gentamicin-treated patients and colistin
resistance in one of 16 colistin-treated patients).
Conclusion
Based on studies performed in ICUs with low levels of
antibiotic resistance – mainly from the Netherlands – thereis no evidence that universal use of SDD or SOD increases
antibiotic resistance among GNB, neither in individual
patients or at ICU level. The evidence base for the effects
of selective decontamination in ICUs where MDR-GNB are
endemic is limited to observational data and one small
RCT, all on SDD, yielding contradicting results. Targeted
SDD for patients colonized with MDR-GNB has been
studied in RCTs outside the ICU setting, where it seemed
to result in short-term benefits only, with associated risks
of resistance development to the antibiotics used. There is
therefore currently insufficient evidence to recommend the
use of SDD in settings with high levels of antibiotic resist-
ance or to eradicate carriage with MDR-GNB. For the latter
settings, more well-designed and sufficiently powered
studies are needed. In ICUs with low levels of antibiotic re-
sistance, SDD or SOD should be used only with careful
microbiological monitoring for resistance development.Abbreviations
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